DDInter1491 DDInter1891
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Peginterferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tucatinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Pomalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib